secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001725160-26-000003
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis updates azenosertib program; DENALI Part 2 topline readout expected by year-end 2026
--------------------------------------------------------------------------------

- Completed enrollment in DENALI Part 2a, supporting registration-intended development of azenosertib.
- Aligned with FDA on confirmatory ASPENOVA Phase 3 trial design for Cyclin E1-positive PROC.
- Cash, equivalents and securities of $280.7M as of Sep 30, 2025; runway into late 2027.
- 2026 milestones: Part 2a dose confirmation H1, ASPENOVA initiation H1, Part 2 topline by YE.
- DENALI Part 2, if successful, could support accelerated approval for azenosertib in PROC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000003/0001725160-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000003/zntl-20260106.htm
  HTML page:      https://secwatch.observer/filing/0001725160-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer